Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV002221551 | SCV002499300 | uncertain significance | Familial cancer of breast | 2022-03-09 | reviewed by expert panel | curation | The ATM c.331+7G>A variant has a GnomAD (v2.1.1) is a singleton in gnomAD v2.1.1 and therefore considered rare (PM2_Supporting). In silico splicing predictors (SpliceAI, Donor Loss: 0%, Donor Gain: 0%; NNSplice, no change) predict that this alteration will not have a significant impact on splicing (BP4). In summary, this variant meets criteria to be classified as a variant of uncertain significance. ACMG/AMP criteria applied, as specified by the HBOP Variant Curation Expert Panel. |
Invitae | RCV000536930 | SCV000622409 | likely benign | Ataxia-telangiectasia syndrome | 2023-12-19 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000583644 | SCV000687466 | likely benign | Hereditary cancer-predisposing syndrome | 2016-02-23 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000601434 | SCV000719008 | likely benign | not specified | 2017-04-26 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Myriad Genetics, |
RCV002221551 | SCV005084876 | likely benign | Familial cancer of breast | 2024-04-18 | criteria provided, single submitter | clinical testing | This variant is considered likely benign. This variant is intronic and is not expected to impact mRNA splicing. |